Read the latest from Baszucki Group and its partners.
March 6, 2026 — OPINION: Diagnosed with bipolar disorder, my son began a medically supervised ketogenic regimen — and it sent his symptoms into lasting remission, Jan Ellison Baszucki writes.
Baszucki Group today announced the publication of the first evidence-based expert consensus on the safe and effective implementation of ketogenic therapy for serious mental illness. This Delphi consensus, funded by Baszucki Group and led by Dr. Georgia Ede, provides clinicians with clearer guidance on how metabolic approaches like ketogenic metabolic therapy can be thoughtfully integrated into individualized psychiatric treatment plans alongside existing first-line treatments and within multidisciplinary care teams.
February 6, 2026—Preliminary studies suggest that a high-fat, low-carbohydrate diet could reduce schizophrenia symptoms in some people, but claiming it’s a cure is misleading, experts say
Baszucki Group today announced an expanded commitment to the landmark Cleveland Clinic Brain Study. Launched in 2022, this ambitious longitudinal study plans to follow healthy individuals over a 20-year period with the goal of identifying early disease markers and therapeutic targets needed to prevent and ultimately cure neurological diseases. The commitment from Baszucki Group brings their total donation to the study to $450,000.